

SECOND EDITION

Anticoagulation Therapy

A CLINICAL PRACTICE GUIDE

**WILLIAM E. DAGER, PharmD, BCPS (AQ Cardiology), FCSHP,
FCCP, FCCM, FASHP, MCCM**

Pharmacist Specialist, UC Davis Medical Center
Clinical Professor of Medicine, UC Davis School of Medicine
Sacramento, California
Clinical Professor of Pharmacy
UC San Francisco School of Pharmacy
San Francisco, California
Clinical Professor of Pharmacy, Touro School of Pharmacy
Vallejo, California

MICHAEL P. GULSETH, PharmD, BCPS, FASHP

Program Director for Anticoagulation Services
Department of Pharmaceutical Services
Sanford USD Medical Center
Sioux Falls, South Dakota
Clinical Associate Professor
University of South Dakota Sanford School of Medicine

EDITH A. NUTESCU, PharmD, MS CTS, FCCP

Associate Professor, Department of Pharmacy Systems,
Outcomes and Policy
Director, Center for Pharmacoepidemiology and
Pharmacoeconomic Research
University of Illinois at Chicago, College of Pharmacy
Co-Director, Personalized Medicine Program
University of Illinois Hospital and Health Sciences System
(UI-Health)
Chicago, Illinois

Any correspondence regarding this publication should be sent to the publisher, American Society of Health-System Pharmacists, 4500 East West Highway, Suite 900, Bethesda, MD 20814, attention: Special Publishing.

The information presented herein reflects the opinions of the contributors and advisors. It should not be interpreted as an official policy of ASHP or as an endorsement of any product.

Because of ongoing research and improvements in technology, the information and its applications contained in this text are constantly evolving and are subject to the professional judgment and interpretation of the practitioner due to the uniqueness of a clinical situation. The editors and ASHP have made reasonable efforts to ensure the accuracy and appropriateness of the information presented in this document. However, any user of this information is advised that the editors and ASHP are not responsible for the continued currency of the information, for any errors or omissions, and/or for any consequences arising from the use of the information in the document in any and all practice settings. Any reader of this document is cautioned that ASHP makes no representation, guarantee, or warranty, express or implied, as to the accuracy and appropriateness of the information contained in this document and specifically disclaims any liability to any party for the accuracy and/or completeness of the material or for any damages arising out of the use or non-use of any of the information contained in this document.

Acquisitions Editor: Beth Campbell
Editorial Project Manager: Ruth Bloom
Production Manager: Johnna Hershey
Cover & Page Design: David Wade
Composition: Carol Barrer

Library of Congress Cataloging-in-Publication Data

Names: Dager, William E., editor. | Gulseth, Michael P., editor. | Nutescu, Edith A., editor. | American Society of Health-System Pharmacists, issuing body.

Title: Anticoagulation therapy : a clinical practice guide / [edited by] William E. Dager, Michael P. Gulseth, Edith A. Nutescu.

Other titles: Anticoagulation therapy (Dager)

Description: Second edition. | Bethesda, Maryland : American Society of Health-System Pharmacists, [2018] | Includes bibliographical references and index.

Identifiers: LCCN 2017052407 | ISBN 9781585284894 (pbk. : alk. paper)

Subjects: | MESH: Anticoagulants--therapeutic use | Thromboembolism--drug therapy

Classification: LCC RM335 | NLM

© 2018, American Society of Health-System Pharmacists, Inc. All rights reserved.

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, microfilming, and recording, or by any information storage and retrieval system, without written permission from the American Society of Health-System Pharmacists.

ASHP is a service mark of the American Society of Health-System Pharmacists, Inc.; registered in the U.S. Patent and Trademark Office.

ISBN: 978-1-58528-489-4

10 9 8 7 6 5 4 3 2 1

DEDICATION

Without the continuous support and encouragement from family, colleagues, students, and residents, this book—now in its second edition—could never have come to fruition.

To all the patients who have needed our services and desire to learn and improve their care.

Edith

To my parents who instilled a work ethic and passion to serve others. For my wife Karen and children William R, Jessica, and Laura for their constant encouragement and understanding throughout the years: I am forever grateful.

Bill

To my parents, Daniel and Constance Gulseth: Thank you for showing me the path to take on life—living faithfully, cherishing family, and pursuing worthy opportunities.

Michael

CONTENTS

Contributors	vii
Preface.....	xi
Acknowledgments	xiii
Abbreviations.....	xv

Part I. Anticoagulation Medication Management

1. Introduction to Anticoagulation Management	3
<i>William E. Dager, Michael P. Gulseth, and Edith A. Nutescu</i>	
2. Warfarin.....	13
<i>Ann K. Wittkowsky</i>	
3. Unfractionated Heparin.....	35
<i>William E. Dager</i>	
4. Low Molecular Weight Heparin and Fondaparinux	65
<i>Zachary Stacy and Sara K. Richter</i>	
5. Parenteral Direct Thrombin Inhibitors	85
<i>William E. Dager and A. Joshua Roberts</i>	
6. Thrombolytic Considerations When Used with Anticoagulants	107
<i>Toby C. Trujillo and Tyree H. Kiser</i>	
7. Direct Oral Anticoagulants	131
<i>Allison E. Burnett and Candice L. Garwood</i>	
8. Anticoagulation Reversal: Part I—Pharmacology of Agents Used for Reversal	163
<i>Lance J. Oyen and Scott A. Chapman</i>	
9. Anticoagulation Reversal: Part II—Clinical Application.....	183
<i>William E. Dager</i>	
10. Transitions in Care—Periprocedural Bridging and Transitions Between Agents	223
<i>Jessica Rimsans, Katelyn W. Sylvester, and John Fanikos</i>	
11. Considerations in Special Populations.....	251
<i>Thaddaus Hellwig and William E. Dager</i>	

Part II. Conditions Requiring Anticoagulation Therapy

12. Venous Thromboembolism Prevention	283
<i>Paul P. Dobesh and Kelsey Aker</i>	
13. Venous Thromboembolism Treatment.....	313
<i>Snehal H. Bhatt and Michael P. Gulseth</i>	
14. Atrial Fibrillation	347
<i>Daniel M. Witt</i>	
15. Acute Coronary Syndromes.....	363
<i>Sarah A. Spinler</i>	
16. Prosthetic Heart Valves	393
<i>Douglas C. Anderson</i>	

CONTENTS (continued)

17. Mechanical Circulatory Support Devices	405
<i>Christopher Paciullo, Laura Baumgartner, and Lauren Roller</i>	
18. Heparin-Induced Thrombocytopenia	423
<i>William E. Dager</i>	
19. Pregnancy.....	449
<i>Nancy L. Shapiro</i>	
20. Pediatrics.....	481
<i>Kirsten H. Ohler</i>	

Part III. Practical Measuring, Monitoring, and Coagulation Laboratory Insights

21. Coagulation Laboratory Considerations	507
<i>Robert C. Gosselin and Maureen A. Smythe</i>	
22. Thrombophilias.....	549
<i>Jessica B. Michaud and Canice A. Coan</i>	

Part IV. Essentials for Practice Success

23. Models and Standards of Anticoagulation Care Delivery	577
<i>Nathan P. Clark and Paul B. Shaw</i>	
24. Regulatory and Practice Resources	605
<i>Michael P. Gulseth and William E. Dager</i>	

Appendixes

Appendix A. Coagulation Cascade	617
Appendix B. Agents Implicated in Drug-Induced Thromboembolic Diseases.....	618
Appendix C. Nutrition Influence on Anticoagulation	623
Appendix D. Anticoagulants in Management of Ischemic Stroke or Transient Ischemic Attacks	625
Appendix E. Citrate Anticoagulation.....	627
Appendix F. Examples of Available Bleeding Definitions.....	629
Appendix G. Types of CNS Hemorrhage	631
Appendix H. Disseminated Intravascular Coagulation	632
Appendix I. Nondrug Causes of Thrombocytopenia	633
Appendix J. Drug-Related Causes of Thrombocytopenia.....	634
Appendix K. Examples of Transfusion-Related Reactions	637
Appendix L. Considerations for Transitioning from aPTT to Anti-Xa to Manage Heparin Therapy	638
Appendix M. PIONEER AF-PCI	641
Appendix N. Betrixaban APEX Trial.....	642
Index.....	643

CONTRIBUTING EDITORS

WILLIAM E. DAGER, PharmD, BCPS (AQ CARDIOLOGY), FCSHP, FCCP, FCCM, FASHP, MCCM

Pharmacist Specialist, UC Davis Medical Center
Clinical Professor of Medicine
UC Davis School of Medicine
Sacramento, California
Clinical Professor of Pharmacy
UC San Francisco School of Pharmacy
San Francisco, California
Clinical Professor of Pharmacy
Touro School of Pharmacy
Vallejo, California

MICHAEL P. GULSETH, PharmD, BCPS, FASHP

Program Director for Anticoagulation Services
Department of Pharmaceutical Services
Sanford USD Medical Center
Sioux Falls, South Dakota
Clinical Associate Professor
University of South Dakota Sanford School of Medicine

EDITH A. NUTESCU, PharmD, MS CTS, FCCP

Associate Professor
Department of Pharmacy Systems, Outcomes and Policy
Director, Center for Pharmacoepidemiology and Pharmacoeconomic Research
University of Illinois at Chicago, College of Pharmacy
Co-Director, Personalized Medicine Program
University of Illinois Hospital and Health Sciences System (UI-Health)
Chicago, Illinois

CONTRIBUTORS

Kelsey Aker, PharmD

Critical Care Pharmacist
Department of Pharmaceutical and Nutritional
Care
Nebraska Medicine
Omaha, Nebraska

Douglas C. Anderson, PharmD, DPh

Professor and Chair
Department of Pharmacy Practice
Cedarville University School of Pharmacy
Cedarville, Ohio

Laura Baumgartner, PharmD, BCPS, BCCCP

Assistant Professor, Department of Clinical
Sciences
Touro University California College of Pharmacy
Vallejo, California

Snehal H. Bhatt, PharmD, FASHP, BCPS (AQ-Cardiology)

Associate Professor of Pharmacy Practice
MCPHS University
School of Pharmacy–Boston
Boston, Massachusetts

CONTRIBUTORS (continued)

Allison E. Burnett, PharmD, PhD, CACP

Antithrombosis Stewardship Pharmacist
University of New Mexico Hospital
Clinical Assistant Professor
University of New Mexico College of Pharmacy
Albuquerque, New Mexico

Scott A. Chapman, PharmD

Associate Professor
Experimental and Clinical Pharmacology
University of Minnesota
College of Pharmacy
Minneapolis, Minnesota

Nathan P. Clark, PharmD, FCCP, BCPS

Clinical Pharmacy Supervisor
Anticoagulation and Anemia Management
Services
Kaiser Permanente Colorado
Aurora, Colorado

Canice A. Coan, PharmD, BCACP

PCMH Pharm Case Management Coordinator
Clarkson Family Medicine, Brentwood Village,
and Chalco
UNMC COP Clinical Assistant Professor -
Pharmacy Practice
Nebraska Medicine
Nebraska Medical Center
Omaha, Nebraska

**Paul P. Dobesh, PharmD, FCCP, BCPS
(AQ Cardiology)**

Professor of Pharmacy Practice
College of Pharmacy
University of Nebraska Medical Center
Omaha, Nebraska

John Fanikos, RPh, MBA

Executive Director of Pharmacy
Brigham and Women's Hospital
Department of Pharmacy Services
Boston, Massachusetts

Candice L. Garwood, PharmD, FCCP, BCPS

Associate Professor (Clinical)
Eugene Applebaum College of Pharmacy and
Health Sciences, Wayne State University
Detroit, Michigan

Robert C. Gosselin, CLS

Clinical Laboratory Scientist
Hemophilia Treatment Center
Division of Hematology/Oncology
UC Davis Health System
Sacramento, California

Thaddaus Hellwig, PharmD, BCPS

Associate Professor
South Dakota State University
College of Pharmacy and Allied Health
Professions
Sanford USD Medical Center
Sioux Falls, South Dakota

Tyree H. Kiser, PharmD, FCCM, FCCP, BCPS

Associate Professor
Department of Clinical Pharmacy
University of Colorado Skaggs School of
Pharmacy and Pharmaceutical Sciences
Aurora, Colorado

Jessica B. Michaud, PharmD, BCPS

Clinical Pharmacist
Rheumatology Clinic
Anticoagulation & Medication Therapy Clinic
Froedtert & Medical College of Wisconsin
Milwaukee, Wisconsin

Kirsten H. Ohler, PharmD, BCPS, BCPPS

Clinical Associate Professor
Program Director, PGY2 Pediatric Pharmacy
Residency
Department of Pharmacy Practice
University of Illinois at Chicago, College of
Pharmacy
Clinical Pharmacist, Neonatal Intensive Care
University of Illinois Hospital & Health Sciences
System
Chicago, Illinois

Lance J. Oyen, PharmD, BCPS, FCCM, FCCP

Associate Chief Pharmacy Officer - Clinical
Services & Research, Department of
Pharmacy
Associate Professor of Pharmacy, Mayo College
of Medicine
Mayo Clinic
Rochester, Minnesota

CONTRIBUTORS (continued)

Christopher Paciullo, PharmD, BCCCP, FCCM, FCCP

Pharmacy Manager
Emory University Hospital Midtown
Atlanta, Georgia

Sara K. Richter, PharmD, BCPS

Assistant Professor, Pharmacy Practice
St. Louis College of Pharmacy
St. Louis, Missouri

Jessica Rimsans, PharmD, BCPS

Clinical Specialist
Department of Pharmacy
Brigham and Women's Hospital
Boston, Massachusetts

A. Joshua Roberts, PharmD, BCPS (AQ Cardiology)

Senior Clinical Pharmacist
University of California
Davis Medical Center
Associate Clinical Professor of Pharmacy
University of California
San Francisco School of Pharmacy
San Francisco, California

Lauren Roller, PharmD, BCCCP

Assistant Professor
Department of Clinical Sciences
Touro University California
Vallejo, California

Nancy L. Shapiro, PharmD, FCCP, BCACP, CACP

Clinical Associate Professor
Pharmacy Practice
Coordinator and Clinical Pharmacist
Antithrombosis Clinic
PGY2 Ambulatory Care Residency Director
University of Illinois at Chicago
Chicago, Illinois

Paul B. Shaw, PharmD, BCPS

Clinical Pharmacy Supervisor - Cardiology
Kaiser Permanente Colorado
Lafayette, Colorado

Maureen A. Smythe, PharmD, FCCP

Anticoagulation Specialist
Department of Pharmaceutical Services
Beaumont Hospital
Royal Oak, Michigan
and
Professor (Clinical)
Department of Pharmacy Practice
Wayne State University
Detroit, Michigan

Sarah A. Spinler, PharmD, FCCP, FAHA, FASHP, AACC, BCPS (AQ-Cardiology)

Professor Emeritus
Philadelphia College of Pharmacy
University of the Sciences
Philadelphia, Pennsylvania

Zachary Stacy, PharmD, MS, FCCP, BCPS

Associate Professor of Pharmacy Practice
St. Louis College of Pharmacy
St. Louis, Missouri

Katelyn W. Sylvester, PharmD, CACP, BCPS

Pharmacy Manager
Department of Pharmacy
Brigham and Women's Hospital
Boston, Massachusetts

Toby C. Trujillo, PharmD, FCCP, FAHA, BCPS (AQ Cardiology)

Associate Professor
University of Colorado
Skaggs School of Pharmacy and Pharmaceutical Sciences
Clinical Specialist - Anticoagulation/Cardiology
University of Colorado Hospital
Aurora, Colorado

Daniel M. Witt, PharmD, FCCP, BCPS

Professor and Chair, Pharmacotherapy
Assistant Dean of Clinical Affairs
University of Utah
L. S. Skaggs Pharmacy Institute
Salt Lake City, Utah

CONTRIBUTORS (continued)

**Ann K. Wittkowsky, PharmD, CACP, FASHP,
FCCP**

Director, Anticoagulation Services
UWMedicine Department of Pharmacy
Clinical Professor
University of Washington School of Pharmacy
Seattle, Washington

PREFACE

Ensuring the safe and appropriate use of anticoagulants continues to be major challenge. Despite the release of the direct-acting oral anticoagulants (DOACs), which many hoped would improve patient safety, in 2016 the U.S. Food and Drug Administration (FDA) Adverse Event Reporting System received 18,878 reports of anticoagulant-related serious injury and 3018 deaths.¹ In a recent study by the Centers for Disease Control and Prevention, anticoagulants accounted for 17.6% of all U.S. emergency department visits, and nearly half of these patients needed to be hospitalized.² The increasing complexity of patients and advances in technologies, such as cardiac circulatory devices, has made anticoagulant management approaches even more challenging. We (the editors) are clinicians and face the challenge of using anticoagulants in a safe and effective way on a daily basis. From this experience, we decided now was the right time to update our practical guide on anticoagulation drug therapy. Our goal is to give the clinician quick access to evidence-based and/or expert opinion information for the challenging clinical situations they may face.

New features of this second edition include:

- Extensive new information on the DOACs—most agents were not approved when the first edition was written
- Expanded information on anticoagulation reversal due to the release of DOACs and expanded options in management
- Five new chapters on the following topics:
 - Use of anticoagulants, including DOACs, in special patient populations
 - Use of anticoagulants in patients with mechanical devices
 - Anticoagulation care delivery standards, regulatory issues, and practice resources beyond this text
- Three new appendixes covering:
 - Nutritional influences with anticoagulation, types of central nervous system hemorrhage, and transitioning heparin measurements using the anti-factor Xa instead of the aPTT

As with the first edition, the book is:

- *Light on text.* The amount of “book style text” was intentionally minimized so a clinician did not have to read a whole chapter to find the “one nugget” they were seeking.
- *Heavy on tables/figures.* Our hope is that this allows the clinician to rapidly find the answers they are seeking.
- *Easy to find key points.* Clinical pearls and highlighted key references make it easy to find critical information.
- *Easy to digest.* The use of bullets and clinical pearl examples both present the information in a succinct fashion, and highlight how the information applies to real-life care.
- *Comprehensive.* Although no text can cover every foreseeable topic, this book covers a lot of the potential challenges that clinicians face.

PREFACE (continued)

- *Expertly written.* All the authors are experts in the areas in which they are writing, and all chapters were carefully reviewed by the editors including the chapters written by other editors.
- *Applicable to patients across the continuum of care.* This book covers topics as diverse as how to care for the ambulatory patient in need of anticoagulation bridging for an invasive procedure to the pediatric patient on extracorporeal membrane oxygenation.
- *Useful to a broad scope of disciplines.* This handbook was intentionally designed to be a useful guide for clinicians in any discipline caring for patients on anticoagulation therapy.

The editors are deeply indebted to the authors who were *again* willing to take on one more project and provide their expertise to improve the care of patients receiving anticoagulation therapy. We can never repay them for the time they took away from family and other professional commitments.

Finally, as with the first edition, we must say thank you to all clinicians who tackle the challenges these medications pose on a daily basis. There is no such thing as a “safe” anticoagulant, yet your efforts are what ensure that these agents are used “safely” and in an evidence-based fashion. For that, we wish to thank you on behalf of your patients.

William E. Dager

Michael P. Gulseth

Edith A. Nutescu

References

1. Part II: oral anticoagulants—the nation’s top risk of acute injury from drugs. *Acute Care ISMP Medication Safety Alert!* July 27, 2017;22(15):1-4.
2. Shehab N, Lovegrove MC, Geller AL, et al. U.S. Emergency Department Visits for Outpatient Adverse Drug Events, 2013–2014. *JAMA*. Nov 22 2016;316(20):2115-2125.

ACKNOWLEDGMENTS

The editors would like to acknowledge the assistance provided by these individuals during the preparation of the two editions of this handbook. Your contributions are greatly appreciated.

Lydia D. Chen, PharmD

Lynnette Coolidge, PharmD

Jessica L. Dager

William R. Dager

Ashley Hansen, PharmD

Hahyoon Kim, PharmD

Amy J. Schwinghammer, PharmD

Samantha N. VanAcker, PharmD

ABBREVIATIONS

A	apixaban
AAOS	American Association of Orthopedic Surgery
AAP	American Academy of Pediatrics
ACA	anticardiolipin antibody (also often abbreviated as aCL)
ACC	American College of Cardiology
ACC/AHA	American College of Cardiology/American Heart Association
ACCP	American College of Chest Physicians
ACS	acute coronary syndrome
ACT	activated clotting time
AF	atrial fibrillation
AFFIRM	Atrial Fibrillation Follow-up Investigation of Rhythm Management
AHA	American Heart Association
AHA/ASA	American Heart Association/American Stroke Association
AIS	arterial ischemic stroke
ALL	acute lymphoblastic leukemia
ALT	alanine aminotransferase
AMI	acute myocardial infarction
AP	antiplatelet
APC	activated protein C
APLA syndrome	antiphospholipid antibody syndrome (also often abbreviated APS and APLS)
APLAs	antiphospholipid antibodies
aPTT	activated partial thromboplastin time
ASA	aspirin
ASSENT	Assessment of the Safety and Efficacy of a New Thrombolytic
AST	aspartate aminotransferase
AT	antithrombin
AUC	area under the serum concentration versus time curve
AVR	aortic valve replacement
BID	twice daily dosing
BMI	body mass index
BP	blood pressure

ABBREVIATIONS (continued)

CABG	coronary artery bypass graft
CAD	coronary artery disease
CAP	College of American Pathologists
CBC	complete blood count (including platelets)
CBS	cystathionine- β -synthase
CHD	coronary heart disease
CI	confidence interval
CLIA	Clinical Laboratory Improvement Amendments
CLSI	Clinical Laboratory Standards Institute (formerly NCCLS or National Committee on Clinical Laboratory Standards)
C_{max}	maximum serum concentration
CPK	creatinine phosphokinase
CPR	cardiopulmonary resuscitation
CrCl	creatinine clearance
CRRT	continuous renal replacement technique
CRUSADE	Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines
CSCT	colloidal-silica clotting time
CT	computed tomographic
CVA	cerebrovascular accident
CVAD	central venous access device
CVL	central venous line
D	dabigatran
D5W	5% dextrose in water
DBP	diastolic blood pressure
Dec	decrease
DIC	disseminated intravascular coagulation
dL	deciliter
DOAC	direct-acting oral anticoagulant
dPT	dilute prothrombin time
dRVVT	dilute Russell's viper-venom time
DTI	direct thrombin inhibitor

ABBREVIATIONS (continued)

DVT	deep vein thrombosis
ECG	electrocardiogram
ECLS	extracorporeal life support
ECMO	extracorporeal membrane oxygenation
ELISA	enzyme-linked-immunosorbent assay
Enox	enoxaparin
EU	European Union
FDA	Food and Drug Administration
FFP	fresh frozen plasma
FVL	factor V Leiden mutation
GAGs	glycosaminoglycans
GCS	Glasgow Coma Scale
GCS	graduated compression stockings
GI	gastrointestinal
Gp IIb/IIIa	glycoprotein IIb/IIIa receptor
GUSTO	global use of strategies to open occluded coronary arteries
HAT	heparin-associated thrombocytopenia (nonimmune mediated)
Hct	hematocrit
Hgb	hemoglobin
HIT	heparin-induced thrombocytopenia (immune mediated)
HITTS	heparin-induced thrombocytopenia thrombosis syndrome (immune mediated)
hr	hour
HR-ACT	high response activated clotting time
HR	heart rate
HTN	hypertension
IBD	inflammatory bowel disease
ICD	implantable cardioverter defibrillator
ICH	intracranial hemorrhage
IgG (IgA, etc.)	immune globulin G, etc.
IM	intramuscular
Inc	increase

ABBREVIATIONS (continued)

INR	international normalized ratio
IPC	intermittent pneumatic compression
ISI	International Sensitivity Index
ISTH	International Society of Thrombosis and Haemostasis
IUGR	intrauterine growth restriction
IV	intravenous
IVC	inferior vena cava
KCT	kaolin clotting time
kD	kilodalton
kg	kilogram
kg/m²	kilogram/meter squared
LA	lupus anticoagulant
LIA	latex immunoassay
LMWH	low molecular weight heparin
LR ACT	low range activated clotting time
LV	left ventricular
mg	milligrams
Mg	magnesium
MI	myocardial infarction
min	minutes
mL/min	milliliter/minute
MODS	multiple organ dysfunction syndrome
MRI	magnetic resonance imaging
MTHFR	methylene-tetrahydrofolate reductase
MVP	mechanical valve prosthesis
MVR	mitral valve replacement
NA	not applicable
NHP	normal human plasma
NIBSC	National Institute of Biological Standards and Controls
NINDS	National Institute of Neurological Disorders and Stroke
NPSG	National Patient Safety Goal

ABBREVIATIONS (continued)

NS	normal saline
NSAIDs	nonsteroidal anti-inflammatory drugs
NSR	normal sinus rhythm
NSTE	non-ST-segment elevation
NSTEMI	non-ST-segment elevation myocardial infarction
OR	operation room
PAD	peripheral arterial disease
PCC	prothrombin complex concentrate
PCI	percutaneous coronary intervention
PE	pulmonary embolism
PF-4	platelet factor 4
PICC	peripherally inserted central catheter
Plt	platelet
POC	point of care
PPH	primary pulmonary hypertension
PRBCs	packed red blood cells
PT	prothrombin time
Pt yr	patient-year
R	rivaroxaban
RACE	RAte Control vs. Electrical cardioversion for persistent atrial fibrillation study
RCT	randomized clinical trial
rFVIIa	recombinant factor VII activated
RRR	relative risk reduction
rt-PA	recombinant tissue plasminogen activator
RVT	renal vein thrombosis
SBP	systolic blood pressure
SC	subcutaneous
SCAI	Society for Cardiac Angiography and Interventions
SCD	sickle cell disease
SCr	serum creatinine
sec	seconds

ABBREVIATIONS (continued)

SOB	shortness of breath
sub-Q	subcutaneous
SRA	serotonin release assay
SSC	Scientific Subcommittee (part of ISTH)
SSRI	selective serotonin reuptake inhibitors
STEMI	ST-segment elevation myocardial infarction
T_{1/2}	elimination half life
TAVR	transcatheter aortic valve replacement
TBW	total body weight
TE	thromboembolism
TEE	transesophageal echocardiography
THR	total hip replacement
TIA	transient ischemic attack
TIMI	thrombolysis in myocardial infarction
TKR	total knee replacement
TMA	thrombotic microangiopathy
T_{max}	time to maximum serum concentration
TNK	tenecteplase
tPA	tissue plasminogen activator
TPN	total parenteral nutrition
TT	thrombin time
TTE	transthoracic echocardiography
UFH	unfractionated heparin
units	International Units
Vit K	vitamin K or phytonadione
VKA	vitamin K antagonist
VKOR	vitamin K epoxide reductase
VTE	venous thromboembolism
vWF	von Willebrand's factor
WARSS/APASS	Warfarin vs. Aspirin Recurrent Stroke Study/Antiphospholipid Antibodies in Stroke Study
WHO	World Health Organization

PART I.

ANTICOAGULATION MEDICATION MANAGEMENT

1. Introduction to Anticoagulation Management

2. Warfarin

3. Unfractionated Heparin

4. Low Molecular Weight Heparin and Fondaparinux

*5. Parenteral Direct
Thrombin Inhibitors*

*6. Thrombolytic
Considerations When
Used with Anticoagulants*

7. Direct Oral Anticoagulants

*8. Anticoagulation Reversal: Part I—
Pharmacology of Agents Used for Reversal*

*9. Anticoagulation Reversal:
Part II—Clinical Application*

*10. Transitions in Care—Periprocedural
Bridging and Transitions Between Agents*

11. Considerations in Special Populations



